A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Phase 2 Completed 194 enrolled Pfizer

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Timeline

Start: 2019-12-02
Primary completion: 2022-01-10
Completion: 2022-01-10

Outcome

Met primary endpoint

registry Placebo vs PF-06700841 45mg QD; p = 0.0298; Risk Difference (RD) 18.7 (90% CI 2.7 to 34.6) NCT04092452 ↗

Publications

Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B. Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa. NEJM Evid. 2024 Mar;3(3):EVIDoa2300155. doi: 10.1056/EVIDoa2300155. Epub 2024 Feb 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brepocitinib	Small molecule	45 mg	—
Subject	ROPSACITINIB	Small molecule	400 mg	—
Subject	ZIMLOVISERTIB	Small molecule	400 mg	—